To include your compound in the COVID-19 Resource Center, submit it here.

Movectro cladribine tablets regulatory update

Merck KGaA's Merck Serono S.A. division said it will no longer seek worldwide approval of its cladribine tablets to treat relapsing-remitting multiple sclerosis (RRMS) based on feedback from FDA and EMA. The pharma said fulfilling the agencies' requirements

Read the full 382 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE